Alaunos Therapeutics (TCRT) Non-Current Assets (2009 - 2026)

Alaunos Therapeutics has reported Non-Current Assets for 17 years, with the latest figure at $913000.0 in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 13.3% year-over-year to $913000.0; the trailing twelve-month figure through Mar 2026 stood at $3.9 million (up 272.93% YoY), and the FY2025 full-year result was $978000.0, changed N/A from the prior year.
• Non-Current Assets for Q1 2026 stood at $913000.0, down from $978000.0 in the prior quarter.
• The five-year high for Non-Current Assets was $15.2 million in Q1 2022, with the low at $2000.0 in Q4 2023.
• Historically, Non-Current Assets has averaged $6.3 million across 4 years, with a median of $6.6 million in 2023.
• Annual changes were most pronounced in 2022 — Non-Current Assets decreased 3.44% — and 2023, when it slumped 99.98%.
• Alaunos Therapeutics' Non-Current Assets stood at $11.1 million in 2022, then tumbled by 99.98% to $2000.0 in 2023, then soared by 48800.0% to $978000.0 in 2025, then retreated by 6.65% to $913000.0 in 2026.
• The last three Non-Current Assets figures came in at $913000.0 (Q1 2026), $978000.0 (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.